Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice

Journal of Surgical Oncology

Volumn 67, Issue 2, 1998, Pages 104-111

  Chahinian, A Philippe ^a   Mandeli, John P ^a   Gluck, Harry ^a   Naim, Houshmand ^a   Teirstein, Alvin S ^a   Holland, James F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; Malignant mesothelioma; Nude mouse; Paclitaxel; Suramin

Indexed keywords

CISPLATIN; PACLITAXEL; SURAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; INTRAPERITONEAL DRUG ADMINISTRATION; MESOTHELIOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROSARCOMA; HUMANS; MESOTHELIOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PACLITAXEL; PLEURAL NEOPLASMS; SARCOMA; SURAMIN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031888788     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199802)67:2<104::AID-JSO6>3.0.CO;2-E     Document Type: Article

References (35)

1. Chahinian AP, Rusch VW: Malignant mesothelioma. In: Holland JF, Frei E III, Bast RC, Kufe DW, Morton D, Weichselbaum RR (eds): "Cancer Medicine." 4th Ed. Philadelphia: Lea & Febiger, 1997;1805-1826.
2. Nicholson WJ, Perkel G, Selikoff IJ: Occupational exposure to asbestos. Population at risk and projected mortality - 1980-2030. Am J Ind Med 1982;3:259-311.
3. Chahinian AP, Beranek JT, Suzuki Y, et al.: Transplantation of human malignant mesothelioma into nude mice. Cancer Res 1980; 40:181-185.
4. Chahinian AP, Norton L, Holland JF, et al.: Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma. Cancer Res 1984;44:1688-1692.
5. Sklarin NT, Chahinian AP, Feuer EJ, et al.: Augmentation of activity of cisdiamminedichloroplatinum (II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res 1988;48:64-67.
6. Chahinian AP, Kirschner PA, Gordon RE, et al.: Usefulness of the nude mouse in mesothelioma based on a direct patient xenograft comparison. Cancer 1991;68:558-560.
7. Chahinian AP: The nude mouse model in mesothelioma research and therapy. Eur Respir Rev 1993;3:204-207.
8. Chahinian AP: Therapeutic studies of malignant mesothelioma in nude mice. In: Jaurand M-C, Bignon J (eds): "The Mesothelial Cell and Mesothelioma. Lung Biology in Health and Disease." Vol 78. New York: Marcel Dekker, 1994;285-295.
9. Morocz IA, Lauber B, Schmitter D, Stahel RA: Effect of suramin treatment on mesothelioma and other lung cancer derived cell lines. Eur Respir Rev 1993;3:213-215.
10. Stein CA, LaRocca RV, Thomas R, et al.: Suramin. An anticancer drug with a unique mechanism of action. J Clin Oncol 1989;7: 499-508.
11. Stein CA: Suramin. A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993;53:2239-2248.
12. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 1995;332:1004-1014.
13. Suzuki Y, Chahinian AP, Ohnuma T: Comparative studies of human malignant mesothelioma in vivo, in xenografts in nude mice and in vitro. Cell origin of malignant mesothelioma. Cancer 1987;60:334-344.
14. Riondel J, Jacrot M, Picot F, et al.: Therapeutic response to Taxol of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol 1986;17:137-142.
15. Geran RI, Greenberg NH, Macdonald MM, et al.: Protocols for screening chemical agents and natural products against animal tumors and other biological systems (Ed. 3). Cancer Chemother Rep (Part 3) 1972;3:1-103.
16. Zar JH: Multiple comparisons. In "Biostatistical Analysis." 2nd Ed. Englewood Cliffs. NJ: Prentice-Hall, 1984;185-205.
17. Chahinian AP, Antman K, Goutsou M, et al.: Randomized Phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993;11:1559-1565.
18. Rusch VW, Saltz L, Venkatraman E, et al.: A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994;12:1156-1163.
19. Rice TW, Adelstein DJ, Kirby TJ, et al.: Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1994;58:24-29.
20. Markman M, Kelsen D: Intraperitoneal cisplatin and mitomycin as treatment for malignant peritoneal mesothelioma. Reg Cancer Treat 1989;2:49-53.
21. Markman M, Kelsen D: Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992;118:547-550.
22. Hand AMS, Husgalvel-Pursiainen K, Pelin K, et al.: Interferon-α and -Γ in combination with chemotherapeutic drugs. In vitro sensitivity studies in four human mesothelioma cell lines. Anticancer Drugs 1992;3:687-694.
23. Christmas TI, Musk AW, Robinson BWS: Phase II study of recombinant human alfa interferon therapy in malignant pleural mesothelioma. Proc Am Assoc Cancer Res 1990;31:283A.
24. Boutin C, Nussbaum E, Monnet I, et al.: Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994;74:2460-2467.
25. Soulié P, Ruffié P, Trandafir L, et al.: Combined systemic chemoimmunotherapy in advanced pleural diffuse malignant mesothelioma. Report of a Phase I-II study of weekly cisplatin/ interferon alfa-2a. J CHn Oncol 1996;14:878-885.
26. Pass HI: Contemporary approaches in the investigation and treatment of malignant pleural mesothelioma. Chest Surg Clin North Am 1994;4:497-515.
27. Vogelzang NJ, Herndon J, Clamon et al:. Paclitaxel (Taxol) for malignant mesothelioma. A Phase II study of the Cancer and Leukemia Group B. Proc Am Soc Clin Oncol 1994;13:405A.
28. Van Meerbeeck J, Debruyne C, Van Zandwijk N, et al.: Paclitaxel for malignant pleural mesothelioma. A Phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996;74: 961-963.
29. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
30. Rose WC: Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. Monog Natl Cancer Inst 1993; 15:47-53.
31. Giovanella BC, Stehlin JS Jr, Williams LJ, et al.: Heterotransplantation of human cancers into nude mice. A model system for human cancer chemotherapy. Cancer 1978;42:2269-2281.
32. Ovejera AA, Houchens DP, Barker AD: Chemotherapy of human tumor xenografts in genetically athymic mice. Ann Clin Lab Sci 1978;8:50-56.
33. Steel GG, Courtenay VD, Peckham MJ: The response to chemotherapy of a variety of human tumor xenografts. Br J Cancer 1983;47:1-13.
34. Shorthouse AJ, Peckham MJ, Smyth JF, Steel GG: The therapeutic response of bronchial carcinoma xenografts. A direct patient-xenografts comparison. Br J Cancer 1980;41(suppl IV):142-145.
35. Goldsmith MA, Slavik M, Carter SK: Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 1975;35:1354-1364.